Efficacy of the neutrophil-lymphocyte ratio on biochemical recurrence in patients treated with radical prostatectomy
Keywords:
prostate cancer, biochemical recurrence, neutrophil, lymphocyteAbstract
Objective: Radical prostatectomy (RP) is considered as the gold standard method in the treatment of localized prostate cancer in patients with more than 10 years’ life expectancy. Biochemical recurrence (BCR) is seen in patients followed up after surgery and additional treatment is required for these patients. In our study, we aimed to evaluate those who were clinically diagnosed with localized prostate cancer, had an RP operation and then developed biochemical recurrence; we also aimed to determine the efficacy of the neutrophil-lymphocyte ratio (NLR) to predict BCR. Materials and Methods: The data of 996 patients diagnosed with prostate cancer in our clinic were analyzed retrospectively. Age, PSA value before transrectal ultrasonography guided prostate biopsy, digital rectal examination, Gleason score on biopsy, neutrophil and lymphocyte values detected by preoperative routine hemogram analysis, date of RP, pathological examination data of RP specimen, PSA values at follow-up after surgery, date of BCR and follow-up period of all patients were recorded. Results: We found that PSA, RP Gleason score and extracapsular spread were significant in predicting BCR in multivariate analysis while other parameters and the NLR were not. Conclusion: NLR did not prove statistically significant in univariate analysis although it was high in the patients with BCR that we evaluated in this study.Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.